Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Regulatory Filings Classification · 52% confidence The document is a corporate press release announcing Valneva’s participation in an upcoming industry event (the 26th World Vaccine Congress). It contains forward-looking statements, media and investor relations contacts, and does not present financial results, regulatory form details, or a report itself. It is not an AGM presentation, earnings release, management change, or other specific filing type. As a general announcement/press release that does not neatly fit other categories, it falls under the fallback “Regulatory Filings” classification (RNS).
2026-03-26 English
Valneva participera à plusieurs événements lors du 25ème World Vaccine Congress de Washington
Regulatory Filings Classification · 80% confidence The document is a corporate press release (“communiqué de presse”) announcing Valneva’s participation in events at the World Vaccine Congress and outlining related presentations and initiatives. It contains no financial results (earnings), no formal regulatory report or filing, no invitation to vote, no share transactions, and no detailed investor presentation deck. It is not an announcement of an attached report (so not an RPA), nor an ESG, M&A, or governance document. Therefore, it falls into the fallback “Regulatory Filings” category (RNS) for miscellaneous corporate announcements that do not fit more specific filing categories.
2026-03-26 French
Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing Phase 3 clinical trial results for a Lyme disease vaccine candidate (PF-07307405/LB6V). It is not a financial report (10-K, interim report, earnings release), not a management or investor presentation, and does not pertain to dividends, share transactions, governance changes, M&A, etc. It is a general regulatory announcement of clinical results and forward-looking plans, which falls under the fallback category “Regulatory Filings (RNS).”
2026-03-23 French
6-K - Valneva SE (0001836564) (Filer)
Regulatory Filings
2026-03-18 English
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
Earnings Release Classification · 95% confidence The document is a comprehensive press release detailing Valneva SE's full-year 2025 audited consolidated financial results. It includes key financial highlights, revenue breakdowns, operational updates, and future financial guidance. While it mentions the filing of an annual report (Form 20-F/URD), the document itself provides the actual financial performance data, management commentary, and detailed business review, which characterizes an Earnings Release (ER) rather than a mere announcement of a report (RPA). FY 2025
2026-03-18 English
Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
Earnings Release Classification · 95% confidence The document is a comprehensive financial announcement from Valneva SE detailing its audited financial results for the fiscal year 2025. It includes key financial highlights, a review of business performance, updates on clinical pipeline candidates (Lyme, Shigella, Zika), and future financial outlooks. While it mentions the filing of a 20-F and URD, the document itself serves as the primary communication of the annual financial performance to the market, which fits the definition of an Earnings Release (ER) or a summary of annual results. Given the depth of the financial data and the timing (post-fiscal year end), it is classified as an Earnings Release. FY 2025
2026-03-18 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.